Effects of empagliflozin treatment on body weight by OSA status at baseline. Model reflects a mixed-model repeated-measures analysis that included terms for baseline weight and baseline HbA1c as linear covariates and baseline eGFR category, geographical region, baseline BMI category, number of weeks reachable with a postrandomization weight measurement, treatment, visit, sleep apnea syndrome at baseline, treatment-by-visit interaction, visit-by-sleep apnea syndrome at baseline interaction, treatment-by-sleep apnea syndrome at baseline interaction, treatment-by-visit by sleep apnea syndrome at baseline interaction, baseline HbA1c-by-visit interaction, and baseline weight-by-visit interaction as fixed effects. P values indicated are for differences in change between empagliflozin and placebo at respective time points. *Adjusted mean (SE) changes from baseline by OSA status at baseline. BL, baseline; E, empagliflozin; P, placebo; W, week.